FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD
Facultad
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (87)
2024
-
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993
2022
-
Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials
Diabetes, Obesity and Metabolism, Vol. 24, Núm. 4, pp. 631-640
-
Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group
Pediatric Research, Vol. 91, Núm. 5, pp. 1069-1077
-
The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS)
Calcified Tissue International, Vol. 110, Núm. 1, pp. 74-86
-
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
Breast Cancer Research and Treatment, Vol. 195, Núm. 1, pp. 55-64
2021
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581
-
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
The Lancet, Vol. 398, Núm. 10300, pp. 583-598
-
Teriparatide
Osteoporotic Fracture and Systemic Skeletal Disorders: Mechanism, Assessment, and Treatment (Springer Nature), pp. 339-359
-
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
The Lancet, Vol. 398, Núm. 10313, pp. 1811-1824
-
Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained
Journal of Bone and Mineral Research, Vol. 36, Núm. 2, pp. 236-243
-
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Clinical Breast Cancer, Vol. 21, Núm. 3, pp. 181-190.e2
2020
-
Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)
Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 3987-3998
-
Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial
Calcified Tissue International, Vol. 106, Núm. 6, pp. 646-654
-
Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c
Journal of Diabetes and its Complications, Vol. 34, Núm. 7
-
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
Breast Cancer Research and Treatment, Vol. 184, Núm. 1, pp. 161-172
-
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
The Lancet Diabetes and Endocrinology, Vol. 8, Núm. 8, pp. 672-682
2019
-
Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Journal of Bone and Mineral Research, Vol. 34, Núm. 4, pp. 632-642
-
Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis
Bone, Vol. 120, pp. 1-8
-
Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies
Calcified Tissue International, Vol. 104, Núm. 2, pp. 193-200